|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Avenue Therapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Avenue Therapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
9-8-2023 Insider Buy |
Fortress Biotech, Inc. >10% Owner |
$0.72
CAGR »
|
$301,255.20 418,410 shares |
9-8-2023 Insider Buy |
Lindsay A. Rosenwald, M.D. Director |
$0.72
CAGR »
|
$251,046.00 348,675 shares |
5-6-2021 Insider Buy |
Neil Herskowitz Director |
$3.99
CAGR »
|
$9,975.00 2,500 shares |
3-10-2020 Insider Buy |
Joseph Walter Vazzano Chief Financial Officer |
$7.96
CAGR »
|
$26,981.66 3,389 shares |
2-27-2020 Insider Buy |
Neil Herskowitz Director |
$8.23
CAGR »
|
$21,085.53 2,561 shares |
4-15-2019 Insider Buy |
Neil Herskowitz Director |
$4.52
CAGR »
|
$4,520.00 1,000 shares |
3-29-2019 Insider Buy |
Neil Herskowitz Director |
$5.11
CAGR »
|
$10,220.00 2,000 shares |
2-25-2019 Insider Buy |
Neil Herskowitz Director |
$5.46
CAGR »
|
$27,300.00 5,000 shares |
12-10-2018 Insider Buy |
Jeffrey Paley Director |
$5.24
CAGR »
|
$78,554.00 15,000 shares |
6-8-2018 Insider Buy |
Lindsay A. Rosenwald, M.D. Director |
$4.28
CAGR »
|
$214,143.41 50,000 shares |
4-25-2018 Insider Buy |
Neil Herskowitz Director |
$3.80
CAGR »
|
$3,800.00 1,000 shares |
10-17-2017 Insider Buy |
Neil Herskowitz Director |
$5.01
CAGR »
|
$5,010.00 1,000 shares |
10-9-2017 Insider Buy |
Neil Herskowitz Director |
$5.24
CAGR »
|
$2,620.00 500 shares |
10-9-2017 Insider Buy |
Lindsay A. Rosenwald, M.D. Director |
$5.58
CAGR »
|
$55,817.00 10,000 shares |
Also See: Institutional Holders of ATXI
Also See: SEC filings
Below we present the annualized performance delivered by Avenue Therapeutics stock since 9-8-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Avenue Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about ATXI being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/11/2023 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$54.00 |
|
End price/share: |
$6.20 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-88.52% |
|
Annualized Gain: |
-141.71% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,148.00 |
|
Years: |
0.62 |
|
Avenue Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Avenue Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding ATXI
|
|